Inositol in women suffering from acne and PCOS: a randomized study

Pezza, M; Carlomagno, Valentina

doi:10.15761/god.1000203

Cited by 6 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CADI scores were reported before and after treatment showing statistically significant improvement in five studies. One study 54 gave a descriptive account of improvement and another study 7 did not report CADI data.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 96 publications fulfilled the inclusion criteria. However, three of these studies used the CADI without reporting data 5–7 . Studies using the CADI were published in > 65 journals, most frequently in the Journal of the European Academy of Dermatology and Venerology (eight articles) and in Dermatology (six articles).…”

Section: Resultsmentioning

confidence: 99%

“…31,32 All studies demonstrated an improvement in CADI scores following intervention. One study 7 did not report CADI data. Despite many studies reporting statistically significant improvement in CADI scores, it is not possible to directly interpret these score changes based on their clinical significance as the minimal clinically important difference (MCID) for CADI is not yet known.…”

Section: Sensitivity To Changementioning

confidence: 99%

See 2 more Smart Citations

Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*

et al. 2021

View full text Add to dashboard Cite

The Cardiff Acne Disability Index (CADI) is a questionnaire designed to measure the quality of life of teenagers and young adults with acne. It has been used clinically and within therapeutic research globally. This review aims to appraise all published data regarding the clinical and research experience of the CADI, its psychometric properties and validation, from its publication in 1992 until September 2020, in a single reference source. A literature search was conducted using MEDLINE via Ovid, PubMed, EBSCOhost, Web of Science and Scopus. All full articles in the English language were included. A total of 96 clinical studies were identified and analysed. The CADI has been used in 44 different countries, including four multinational studies, and has validated translations in 25 languages. Overall, 29 therapeutic interventions have used the CADI, demonstrating its responsiveness to change. The reliability of the CADI has been assessed in 14 studies through test-retest and internal consistency studies. In total, 57 studies have demonstrated aspects of its validity through correlation to other measures, and five studies have investigated the dimensionality of the CADI. There is evidence of high internal consistency, test-retest reliability, responsiveness to change and significant correlation with other objective measures. The minimal clinically important difference and validated score meaning bands have not yet been reported. This information is needed to improve the interpretability of CADI scores for clinical use and in research. The authors of the CADI have also rephrased Question 2 of the measure to ensure inclusivity.What is already known about this topic?• Acne significantly impacts quality of life in patients.• There are several skin-specific and acne-specific instruments used in day-to-day practice and research.• The validation and other measurement properties of the Cardiff Acne Disability Index (CADI) have not been easily accessible.What does this study add?• The CADI has been extensively used and is a reliable and valid tool.• There is a need to develop validated CADI score bands and calculate the minimal clinically important difference.• The CADI authors have rephrased Question 2 to ensure that the wording is inclusive.• There is inconsistent reporting of CADI data and a need for guidelines when reporting and publishing quality-of-life data.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Sensitivity To Changementioning

confidence: 99%

See 1 more Smart Citation

Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Dies geschieht üblicherweise durch den Einsatz kombinierter Kontrazeptiva mit einem Antiandrogen. Dieser Effekt kann offenbar durch die zusätzliche Gabe von Myo-Inositol weiter verstärkt werden [31,36]. Bei Frauen mit Hirsutismus und Kinderwunsch kann ein alleiniger Einsatz von Myo-Inositol erwogen werden.…”

Section: Myo-inositol Und Menschliche Eizell-bzw Spermienqualitätunclassified

Myo-Inositol

Egarter

2018

Gynäkologische Endokrinologie

View full text Add to dashboard Cite

Myo-Inositol Das Isomer Myo-Inositol ist der wichtigste Vertreter aus der Inositol-Familie. Inositol ist seinerseits ein Isomer der Glukose und kommt sowohl in Pflanzen als auch tierischem Gewebe vor. Beispielsweise haben Zitrusfrüchte relative hohe Konzentrationen an Myo-Inositol (120 g Grapefruitsaft enthalten ca. 470 mg Myo-Inositol). Inositol wird aber entgegen früherer Meinung nicht nur über die Nahrung aufgenommen (ca. 1 g täglich), sondern kann vom Körper auch direkt synthetisiert werden wie z. B. in der Niere oder in anderen Organen (insgesamt ca. 2 g täglich; [13]).

show abstract

“…Myo-inositol administration has been widely shown to modulate hormonal fluctuations and improve fertility in patients with PCOS, by correcting insulin resistance [9][10][11]. Inositol helps improve skin condition by reducing hyperandrogenism [12] or many other closely related mechanisms of action. Myo-inositol hexaphosphate (phytic acid) displays antimicrobial and antiinflammatory properties and is a potent inhibitor of 5-α reductase, COX-2, and lipase enzymes [13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Ramanan¹,

Ravi²,

Anbu

et al. 2020

Dermatology Research and Practice

View full text Add to dashboard Cite

Myo-inositol’s role in improving acne by reducing hyperandrogenism has been demonstrated in PCOS patients. Inositol and associated molecules display inhibitory properties against 5-α reductase, COX-2, and lipase enzymes in addition to their antimicrobial and anti-inflammatory properties. However, the role of myo-inositol is not well established in women patients with normal hormone levels but with clinical manifestations of PCOS. In this study, we evaluate the efficacy of Tracnil™, a combination of myo-inositol with folic acid and vitamin D3, in resolving acne in overweight women of menstruation age displaying normal hormone levels. It is a single-arm study conducted at 2 centers including 33 women with acne, hirsutism, and menstrual irregularities. Acne and hirsutism were assessed by manual lesion count, modified Cook’s scale, and modified Ferriman–Gallwey hirsutism score (mFGHS). Hormone levels and safety parameters were assessed throughout the study. Our results show that Tracnil™ monotherapy could drastically reduce acne-related lesions of both inflammatory and noninflammatory types as quickly as 8 weeks. Additionally, it improves hirsutism and menstrual irregularities. Adverse reactions were negligible during the whole study period with no drastic side effects reflected by a modulatory effect on hormone levels. Despite the subjects having normal hormone levels, the acne treatment with myo-inositol and vitamin D3 shows improvement in hirsutism and regularization of menstrual cycle. Therefore, we attribute the mechanism of action of Tracnil™ to modulation of receptor sensitivity to sex hormones or other downstream processing events. Tracnil™ may be considered as a first-line treatment for dermatological manifestations of PCOS even in the absence of significant hormonal abnormalities. This treatment is practically implementable in a dermatologists’s office practise.

show abstract

Inositol in women suffering from acne and PCOS: a randomized study

Cited by 6 publications

References 11 publications

Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*

Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*

Myo-Inositol

Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Contact Info

Product

Resources

About